open access

Vol 6, No 5 (2010)
Review paper
Published online: 2011-01-19
Get Citation

Pathophysiological basis of combination of systemic chemiotherapy with EGFR inhibitors

Marek Z. Wojtukiewicz, Paweł Szambora, Ewa Sierko
Onkol. Prak. Klin 2010;6(5):236-240.

open access

Vol 6, No 5 (2010)
REVIEW ARTICLES
Published online: 2011-01-19

Abstract

Cancer patients treatment using the combination of systemic chemotherapy with EGFR inhibitors still creates multiple questions. To date the exact mechanisms of interactions between the two different therapeutic modalities have not been ultimately explained. It seems that common intercellular apoptosis pathway, inhibition of DNA repair systems, especially double strand breaks, and antiangiogenic effects play an important role in the outcome of such combined antineoplastic therapy.

Onkol. Prak. Klin. 2010; 6, 5: 236–240

Abstract

Cancer patients treatment using the combination of systemic chemotherapy with EGFR inhibitors still creates multiple questions. To date the exact mechanisms of interactions between the two different therapeutic modalities have not been ultimately explained. It seems that common intercellular apoptosis pathway, inhibition of DNA repair systems, especially double strand breaks, and antiangiogenic effects play an important role in the outcome of such combined antineoplastic therapy.

Onkol. Prak. Klin. 2010; 6, 5: 236–240

Get Citation

Keywords

epidermal growth factor receptor; EGFR; chemotherapy; apoptosis; DNA repair systems; angiogenesis

About this article
Title

Pathophysiological basis of combination of systemic chemiotherapy with EGFR inhibitors

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 5 (2010)

Article type

Review paper

Pages

236-240

Published online

2011-01-19

Bibliographic record

Onkol. Prak. Klin 2010;6(5):236-240.

Keywords

epidermal growth factor receptor
EGFR
chemotherapy
apoptosis
DNA repair systems
angiogenesis

Authors

Marek Z. Wojtukiewicz
Paweł Szambora
Ewa Sierko

References (30)
  1. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3): 183–232.
  2. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001; 7(10): 2958–2970.
  3. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003; 21(14): 2787–2799.
  4. Grünwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst. 2003; 95(12): 851–867.
  5. Morelli MP, Cascone T, Troiani T, et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol. 2005; 16 Suppl 4: iv61–iv68.
  6. Humblet Y. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother. 2004; 5(7): 1621–1633.
  7. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351(4): 337–345.
  8. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004; 22(5): 777–784.
  9. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004; 22(5): 785–794.
  10. Herbst RS, Prager D, Hermann R, et al. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2004; 22(14_suppl): 7011.
  11. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007; 25(12): 1545–1552.
  12. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000; 102(1): 1–4.
  13. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2(6): 420–430.
  14. Schilsky RL. Antimetabolites. In: Perry MC. ed. The chemotherapy source book. Williams & Wilkins, Baltimore 1992: 301–315.
  15. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene. 2003; 22(56): 9063–9074.
  16. Ingraham HA, Tseng BY, Goulian M. Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine. Mol Pharmacol. 1982; 21(1): 211–216.
  17. Tibbetts RS, Brumbaugh KM, Williams JM, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 1999; 13(2): 152–157.
  18. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003; 3(5): 421–429.
  19. Kastan MB, Lim DS, Kim ST, et al. Multiple signaling pathways involving ATM. Cold Spring Harb Symp Quant Biol. 2000; 65: 521–526.
  20. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998; 281(5381): 1322–1326.
  21. Mauro DJ, De Riel JK, Tallarida RJ, et al. Mechanisms of excision of 5-fluorouracil by uracil DNA glycosylase in normal human cells. Mol Pharmacol. 1993; 43(6): 854–857.
  22. Boku N, Chin K, Hosokawa K, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res. 1998; 4(6): 1469–1474.
  23. Dickson JLB, Cunningham D. Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol. 2004; 16(3): 255–263.
  24. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004; 305(5687): 1163–1167.
  25. Rutkowski B. Erytropoetyna od odkrycia do zastosowań klinicznych. Makmed, Gdańsk 2001: 16–26.
  26. Bandyopadhyay D, Mandal M, Adam L, et al. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem. 1998; 273(3): 1568–1573.
  27. Yoganathan TN, Costello P, Chen X, et al. Integrin-linked kinase (ILK): a "hot" therapeutic target. Biochem Pharmacol. 2000; 60(8): 1115–1119.
  28. Galetic I, Andjelkovic M, Meier R, et al. Mechanism of protein kinase B activation by insulin/insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase--significance for diabetes and cancer. Pharmacol Ther. 1999; 82(2-3): 409–425.
  29. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3): 183–232.
  30. Jain RK. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science. 2005; 307(5706): 58–62.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl